Drug Profile
Lesogaberan - Astrazeneca
Alternative Names: ARH 061746; AZD 3355Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; University Hospital of South Manchester NHS Foundation Trust
- Class Phosphinic acids; Small molecules
- Mechanism of Action GABA B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cough; Gastro-oesophageal reflux
Most Recent Events
- 18 May 2018 Efficacy data from phase II trial in Cough presented at 114th International Conference of the American Thoracic Society (ATS-2018)
- 01 Sep 2017 AstraZeneca completes a phase II trial in Cough in United Kingdom (PO) (EudraCT2014-005074-11)
- 29 Oct 2010 Discontinued - Phase-I for Gastro-oesophageal reflux in Sweden (PO)